Weekly News Recap #Phispers
FDA rejects first MDMA therapy to treat PTSD; Merck, Curon ink up to US$ 1.3 bn deal for next-gen bispecific antibody
The US Food and Drug Administration (FDA) has declined to approve an MDMA-assisted therapy from Lykos Therapeutics to treat pos...
Impressions : 1813
FDA approves first ever T-cell receptor gene therapy from Adaptimmune, Servier’s brain tumor pill
This week, Adaptimmune clinched gold when it secured the first-ever US Food and Drug Administration (FDA) approval for a T-cell...
Impressions : 1168
US panel accuses China of subsidizing fentanyl production; Nigeria introduces 5-in-1 meningitis vaccine
This week’s news brings a mix of promising advancements and concerning issues. A majority of opioid overdose deaths...
Impressions : 1738
Teva indicted for fueling opioid addiction in NY; Theranos founder pronounced guilty for duping investors
In this first Phispers of 2022, we bring you several
updates on court cases involving pharmaceutical companies such as Teva,
...
Impressions : 1463
India partially lifts Hydroxychloroquine, Paracetamol export ban; delays by FTC lead to nixing of US$ 1 billion Sandoz deal
This week, Phispers has more updates on the deadly novel coronavirus.
The US, which has reported over 400,000 cases of Covid-...
Impressions : 2303
Insys founder sentenced to jail in opioid case; Ipsen’s Clementia bet misfires
This week, Phispers has news on Insys Therapeutics. Indicted for fraud, the founder of the company, John Kapoor, and several ot...
Impressions : 2307
Insys founder Kapoor convicted in opioid scandal; FDA rules changing due to new technologies
This week, Phispers brings you news about John Kapoor, the founder of Insys who was found guilty of engaging in a bribery schem...
Impressions : 3733
PhRMA publishes list of US cancer drug pipeline; Biocon-Mylan’s Neulasta biosim bags FDA nod
This week in Phispers, Biocon–Mylan scored a big win by getting the FDA nod for its biosimilar to Amgen’s Neulasta....
Impressions : 2468
AstraZeneca’s shareholders rebel over CEO pay; FDA lashes out at IQVIA over erroneous data
Soon after
US President Donald Trump revealed his new drug pricing plan, the FDA took a
tough stand by releasing a list of dr...
Impressions : 5177
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.